BACKGROUND: Adenoid cystic carcinoma is a locally aggressive salivary gland neoplasm, which has a poor long-term prognosis. A chromosomal translocation involving the genes encoding the transcription factors, MYB and NFIB, has been recently discovered in these tumors. METHODS: MYB translocation and protein expression were studied in 37 adenoid cystic carcinomas, 112 other salivary gland neoplasms, and 409 nonsalivary gland neoplasms by fluorescence in situ hybridization and immunohistochemistry. MYB translocation and expression status in adenoid cystic carcinoma was correlated with clinicopathologic features including outcome, with a median follow-up of 77.1 months (range, 23.2 to 217.5 mo) for living patients. RESULTS: A balanced translocation between MYB and NFIB is present in 49% of adenoid cystic carcinomas but is not identified in other salivary gland tumors or nonsalivary gland neoplasms. There is no apparent translocation of MYB in 35% of the cases. Strong Myb immunostaining is very specific for adenoid cystic carcinomas but is only present in 65% of all cases. It is interesting to note that Myb immunostaining is confined to the basal cell component although the translocation is present in all the cells. Neoplasms with MYB translocation show a trend toward higher local relapse rates, but the results are not statistically significant with the current number of cases. CONCLUSIONS: MYB translocation and expression are useful diagnostic markers for a subset of adenoid cystic carcinomas. The presence of the translocation may be indicative of local aggressive behavior, but a larger cohort may be required to show statistical significance.
BACKGROUND:Adenoid cystic carcinoma is a locally aggressive salivary gland neoplasm, which has a poor long-term prognosis. A chromosomal translocation involving the genes encoding the transcription factors, MYB and NFIB, has been recently discovered in these tumors. METHODS:MYB translocation and protein expression were studied in 37 adenoid cystic carcinomas, 112 other salivary gland neoplasms, and 409 nonsalivary gland neoplasms by fluorescence in situ hybridization and immunohistochemistry. MYB translocation and expression status in adenoid cystic carcinoma was correlated with clinicopathologic features including outcome, with a median follow-up of 77.1 months (range, 23.2 to 217.5 mo) for living patients. RESULTS: A balanced translocation between MYB and NFIB is present in 49% of adenoid cystic carcinomas but is not identified in other salivary gland tumors or nonsalivary gland neoplasms. There is no apparent translocation of MYB in 35% of the cases. Strong Myb immunostaining is very specific for adenoid cystic carcinomas but is only present in 65% of all cases. It is interesting to note that Myb immunostaining is confined to the basal cell component although the translocation is present in all the cells. Neoplasms with MYB translocation show a trend toward higher local relapse rates, but the results are not statistically significant with the current number of cases. CONCLUSIONS:MYB translocation and expression are useful diagnostic markers for a subset of adenoid cystic carcinomas. The presence of the translocation may be indicative of local aggressive behavior, but a larger cohort may be required to show statistical significance.
Authors: Idoya Lahortiga; Kim De Keersmaecker; Pieter Van Vlierberghe; Carlos Graux; Barbara Cauwelier; Frederic Lambert; Nicole Mentens; H Berna Beverloo; Rob Pieters; Frank Speleman; Maria D Odero; Marijke Bauters; Guy Froyen; Peter Marynen; Peter Vandenberghe; Iwona Wlodarska; Jules P P Meijerink; Jan Cools Journal: Nat Genet Date: 2007-04-15 Impact factor: 38.330
Authors: Sébastien J Hotte; Eric W Winquist; Elizabeth Lamont; Mary MacKenzie; Everett Vokes; Eric X Chen; Shirley Brown; Gregory R Pond; Anthony Murgo; Lillian L Siu Journal: J Clin Oncol Date: 2005-01-20 Impact factor: 44.544
Authors: Robert B West; Brian P Rubin; Melinda A Miller; Subbaya Subramanian; Gulsah Kaygusuz; Kelli Montgomery; Shirley Zhu; Robert J Marinelli; Alessandro De Luca; Erinn Downs-Kelly; John R Goldblum; Christopher L Corless; Patrick O Brown; C Blake Gilks; Torsten O Nielsen; David Huntsman; Matt van de Rijn Journal: Proc Natl Acad Sci U S A Date: 2006-01-06 Impact factor: 11.205
Authors: Chandra Krishnan; John P Higgins; Robert B West; Yasodha Natkunam; Amy Heerema-McKenney; Daniel A Arber Journal: Am J Surg Pathol Date: 2009-11 Impact factor: 6.394
Authors: Marta Persson; Ywonne Andrén; Joachim Mark; Hugo M Horlings; Fredrik Persson; Göran Stenman Journal: Proc Natl Acad Sci U S A Date: 2009-10-19 Impact factor: 11.205
Authors: T Y Chen; M G Keeney; A V Chintakuntlawar; D L Knutson; S Kloft-Nelson; P T Greipp; J A Garrity; D R Salomao; J J Garcia Journal: Eye (Lond) Date: 2017-01-13 Impact factor: 3.775
Authors: Jisun Kim; Felipe C Geyer; Luciano G Martelotto; Charlotte Ky Ng; Raymond S Lim; Pier Selenica; Anqi Li; Fresia Pareja; Nicola Fusco; Marcia Edelweiss; Rahul Kumar; Rodrigo Gularte-Merida; Andre N Forbes; Ekta Khurana; Odette Mariani; Sunil Badve; Anne Vincent-Salomon; Larry Norton; Jorge S Reis-Filho; Britta Weigelt Journal: J Pathol Date: 2017-12-28 Impact factor: 7.996
Authors: A L Ho; L Dunn; E J Sherman; M G Fury; S S Baxi; R Chandramohan; S Dogan; L G T Morris; G D Cullen; S Haque; C S Sima; A Ni; C R Antonescu; N Katabi; D G Pfister Journal: Ann Oncol Date: 2016-08-26 Impact factor: 32.976
Authors: Justin A Bishop; Takenori Ogawa; Edward B Stelow; Christopher A Moskaluk; Wayne M Koch; Sara I Pai; William H Westra Journal: Am J Surg Pathol Date: 2013-06 Impact factor: 6.394